View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 29, 2022

Terumo and GenCure sign agreement for cell and gene therapies

The alliance will use Terumo and GenCure’s capabilities to set up a reference manufacturing centre for BioBridge Global.

Terumo Blood and Cell Technologies and BioBridge Global subsidiary, GenCure, have entered a new partnership agreement to expand and integrate cell and gene therapy manufacturing solutions.

In a bid to meet the growing demand for automated and closed smart systems across the cell and gene therapy (CGT) industry, the companies entered the deal to merge technologies and capabilities.

These smart systems enable response and modification on a real-time basis to the living treatments being produced inside the systems.

In the initial stage, the alliance will use Terumo and GenCure’s capabilities to set up a reference manufacturing centre for BioBridge. This comprises the co-development of core processes and production operations. 

GenCure will be able to offer a comprehensive solution for cell and gene therapy developers using the reference site. 

The site will be located at the process development and cGMP manufacturing facility of GenCure at VelocityTX campus in San Antonio, Texas, US.

To permit in-plant streamlining of processes and user feedback, Terumo will offer various products from its portfolio and also invest in new products and process usage.

GenCure will utilise its well-developed capabilities in cell collection, cell and gene therapy manufacturing and fill-finish equipment of Terumo. 

This will expand its portfolio for developers who need assistance with manufacturing and process optimisation.

The three-year partnership is planned to be conducted in two phases. 

In the first stage, Terumo will be able to choose from its portfolio of automated and closed-cell and gene therapy manufacturing devices and share the services that GenCure offers. 

This combination will aid in addressing the key industry gaps in manufacturing capacity and operational capabilities. 

The second phase will aid GenCure and other subsidiaries of BioBridge to utilise data management solutions and value-added services of Terumo to transition between clinical and production sites by facilitating leukapheresis products’ chain-of-custody/identity and consistency.

Terumo Blood and Cell Technologies Cell Therapy Technologies general manager Delara Motlagh said: “We are now combining our product portfolios, expertise and management to provide a vital link between cell collection sites and cell and gene therapy manufacturing sites while addressing capacity and ensuring GMP production. 

“This will provide a route to deliver cutting-edge cell and gene therapies through pursuing new standards of collection and manufacturing, including quality, consistency and demonstrated scalability.”

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology